Cancer Research and Treatment

Original Article

Gastrointestinal cancer

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer: Dae-Won Lee, Yoojoo Lim, Hwang-Phill Kim, Su Yeon Kim, Hanseong Roh, Jun-Kyu Kang, Kyung‑Hun Lee, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Sae-Won Han, Tae-You Kim; Cancer Res Treat. 2023;55(3):927-938. Published online March 7, 2023; DOI: https://doi.org/10.4143/crt.2023.268

Abstract PDF Supplementary Material PubReader ePub

Purpose
Circulating tumor DNA (ctDNA) is emerging as a valuable non-invasive tool to identify tumor heterogeneity and tumor burden. This study investigated ctDNA dynamics in metastatic colorectal cancer patients treated with regorafenib.
Materials and Methods
In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease were sequenced using a targeted next-generation sequencing platform which included 106 genes.
Results
A total of 285 blood samples from 110 patients were analyzed. Higher baseline cfDNA concentration was associated with worse progression-free survival (PFS) and overall survival (OS). After 2 cycles of treatment, variant allele frequency (VAF) in the majority of ctDNA mutations decreased with a mean relative change of –31.6%. Decreases in the VAF of TP53, APC, TCF7L2, and ROS1 after 2 cycles of regorafenib were associated with longer PFS. We used the sum of VAF at each time point as a surrogate for the overall ctDNA burden. A reduction in sum (VAF) of ≥ 50% after 2 cycles was associated with longer PFS (6.1 vs. 2.7 months, p=0.002), OS (11.3 vs. 5.9 months, p=0.001), and higher disease control rate (86.3% vs. 51.1%, p < 0.001). VAF of the majority of the ctDNA mutations increased at the time of disease progression, and VAF of BRAF increased markedly.
Conclusion
Reduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib.

Citations

Citations to this article as recorded by

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Regorafenib in the Treatment of Metastatic Colorectal Cancer
Bingjun Liang, Ming Tang, Chao Huang, Yidian Yang, Yue He, Shengrong Liao, Weizeng Shen
Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer
Ji-Won Kim, Dong Soo Kyung, Won Yeong Ko, Hwang-Phill Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Keun-Wook Lee
Gastric Cancer.2025;[Epub] CrossRef
Adjuvant therapy for stage IIB + IIC melanoma
Parisa Malekzadeh, Mary S. Brady
Journal of Surgical Oncology.2024; 129(1): 91. CrossRef
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer
Jianxin Zhong, Hanfang Jiang, Xiaoran Liu, Hao Liao, Feng Xie, Bin Shao, Shidong Jia, Huiping Li
Breast Cancer Research and Treatment.2024; 204(3): 617. CrossRef
Stage-Specific Plasma Metabolomic Profiles in Colorectal Cancer
Tetsuo Ishizaki, Masahiro Sugimoto, Yu Kuboyama, Junichi Mazaki, Kenta Kasahara, Tomoya Tago, Ryutaro Udo, Kenichi Iwasaki, Yutaka Hayashi, Yuichi Nagakawa
Journal of Clinical Medicine.2024; 13(17): 5202. CrossRef
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial
Jing Wu, Shilong Zhang, Shan Yu, Guo An, Yi Wang, Yiyi Yu, Li Liang, Yan Wang, Xiaojing Xu, YanShi Xiong, Di Shao, Zhun Shi, Nannan Li, Jingyuan Wang, Dawei Jin, Tianshu Liu, Yuehong Cui
Nature Communications.2024;[Epub] CrossRef
The Diagnostic Utility of cfDNA and ctDNA in Liquid Biopsies for Gastrointestinal Cancers over the Last Decade
Nur Rahadiani, Marini Stephanie, Amelia Fossetta Manatar, Ening Krisnuhoni
Oncology Research and Treatment.2024; 48(3): 125. CrossRef
Mutational evolution after chemotherapy‐progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis
Sheehyun Kim, Yongjun Cha, Yoojoo Lim, Hanseong Roh, Jun‐Kyu Kang, Kyung‐Hun Lee, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Hwang‐Phill Kim, Seung‐Yong Jeong, Kyu Joo Park, Sae‐Won Han, Tae‐You Kim
International Journal of Cancer.2023; 153(3): 571. CrossRef
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
Karen Gambaro, Maud Marques, Suzan McNamara, Mathilde Couetoux du Tertre, Cyrla Hoffert, Archana Srivastava, Anna Schab, Thierry Alcindor, Adrian Langleben, Lucas Sideris, Mahmoud Abdelsalam, Mustapha Tehfe, Felix Couture, Gerald Batist, Petr Kavan
International Journal of Molecular Sciences.2023; 25(1): 43. CrossRef

5,582 View
271 Download
9 Web of Science
9 Crossref

Correspondence

Right Then, Wrong Now: Early-Onset Colorectal Cancer in Korea: Aesun Shin, Kyu-Won Jung, Seung-Yong Jeong; Cancer Res Treat. 2023;55(3):1058-1060. Published online February 6, 2023; DOI: https://doi.org/10.4143/crt.2022.1612

PDF PubReader ePub

Citations

Citations to this article as recorded by

Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data
Hyuna Sung, Rebecca L Siegel, Mathieu Laversanne, Chenxi Jiang, Eileen Morgan, Mariam Zahwe, Yin Cao, Freddie Bray, Ahmedin Jemal
The Lancet Oncology.2025; 26(1): 51. CrossRef
Evaluation of the Antioxidant and Anti-Cancer Potential of Microwave-Assisted Opuntia humifusa (Korean Cheonnyencho) Aqueous Extract
Poojitha Yanamala, Jeong-Yun Youn, Prakash Thangavel, Ju-Young Moon, Young-Chul Lee
Current Issues in Molecular Biology.2025; 47(2): 88. CrossRef
Impact of Small Area Level Deprivation on Colorectal Cancer Survival: Findings from the Regional Cancer Registry in Korea
Seung Min Hong, Ahreum Kim, Changhoon Kim, Seunghye Jang, Dong Uk Kim, Dong Hoon Baek, Seung Hun Lee, Yu Hyeon Yi, Heeseung Park, Jonghyun Lee, Tae In Kim, Hyun Joo Lee
Cancers.2025; 17(4): 567. CrossRef
Incidence and Mortality of Colorectal Cancer in Asia in 2022 and Projections for 2050
Mengxia Fu, Yanping Li, Jian Wang
Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Exploring the nexus between obesity, metabolic syndrome, and colorectal cancer
Jong Yoon Lee
Kosin Medical Journal.2024; 39(1): 18. CrossRef
Clinical and pathological characteristics of early-onset colorectal cancer in South Korea
Su Bee Park, Jin Young Yoon, Min Seob Kwak, Jae Myung Cha
Saudi Journal of Gastroenterology.2023; 29(6): 358. CrossRef
Association or causation: still more questions than answers in early-onset gastrointestinal cancers
E. Fontana, I. Ben-Aharon
ESMO Gastrointestinal Oncology.2023; 1: 40. CrossRef

2,894 View
132 Download
5 Web of Science
7 Crossref

Original Articles

Impact of Mucin Proportion in the Pretreatment MRI on the Outcomes of Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy: Eunji Kim, Kyubo Kim, Se Hyung Kim, Sae-Won Han, Tae-You Kim, Seung-Yong Jeong, Kyu Joo Park, Jaemoon Koh, Gyeong Hoon Kang, Eui Kyu Chie; Cancer Res Treat. 2019;51(3):1188-1197. Published online December 20, 2018; DOI: https://doi.org/10.4143/crt.2018.434

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate treatment response to neoadjuvant chemoradiotherapy (CRT) with regard to mucin status in pathology and pretreatment magnetic resonance imaging (MRI) in locally advanced rectal cancer.
Materials and Methods
Between 2003 and 2011, 306 patients with locally advanced rectal cancer received neoadjuvant CRT followed by surgery, and mucinous adenocarcinoma (MAC) was found in 27 (8.8%). All MAC patients had MRI before and after CRT and mucin proportion at MRI was measured. Therapeutic response was assessed by pathology after total mesorectal excision. To determine the optimal cut-off for mucin proportion in predicting good CRT response (near total or total regression) and negative circumferential resection margin (CRM), the receiver-operating characteristic analysis was performed.
Results
After neoadjuvant CRT, overall downstaging occurred in 44.4% of MAC and 72.4% of non-MAC (p=0.001), and positive CRM (≤1 mm) was observed more frequently in MAC (p<0.001). The optimal threshold for treatment response was 30% for mucin proportion, and there are nine with low mucin proportion (<30%) and 18 with high mucin proportion (≥30%) in pretreatment MRI. Negative CRM and tumor downstaging occurred more common in patients with mucin <30%, although statistically insignificant (p=0.071 and p=0.072, respectively). Regarding oncologic outcomes, lower mucin proportion in pretreatment MRI was associated with better disease-free and overall survival in MAC group (p=0.092 and 0.056, respectively), but the difference did not reach statistical significance.
Conclusion
Poor treatment outcome with neoadjuvant CRT was observed in patients with MAC, especially those with high mucin proportion at pretreatment MRI.

Citations

Citations to this article as recorded by

Mucinous histology is a negative predictor of neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma
Xiangwen Tan, Yiwei Zhang, Xiaofeng Wu, Qing Fang, Yunhua Xu, Shuxiang Li, Jinyi Yuan, Xiuda Peng, Kai Fu, Shuai Xiao
BMC Gastroenterology.2024;[Epub] CrossRef
Incomplete Resection Is Twice as Likely in Locally Advanced Mucinous Compared to Nonmucinous Rectal Adenocarcinoma: A National Propensity‐Matched Analysis
Leah E. Hendrick, Samer Naffouje, Iman Imanirad, Allan Lima Pereira, Tiago Biachi, Julian Sanchez, Sophie Dessureault, Amalia Stefanou, Sean P. Dineen, Seth Felder
Journal of Surgical Oncology.2024;[Epub] CrossRef
Accelerated T2W Imaging with Deep Learning Reconstruction in Staging Rectal Cancer: A Preliminary Study
Lan Zhu, Bowen Shi, Bei Ding, Yihan Xia, Kangning Wang, Weiming Feng, Jiankun Dai, Tianyong Xu, Baisong Wang, Fei Yuan, Hailin Shen, Haipeng Dong, Huan Zhang
Journal of Imaging Informatics in Medicine.2024;[Epub] CrossRef
Mucinous rectal cancers: clinical features and prognosis in a population-based cohort
Malin Enblad, Klara Hammarström, Joakim Folkesson, Israa Imam, Milan Golubovik, Bengt Glimelius
BJS Open.2022;[Epub] CrossRef
Mucin-Containing Rectal Cancer: A Review of Unique Imaging, Pathology, and Therapeutic Response Features
David D. Childs, Caio Max Sao Pedro Rocha Lima, Yi Zhou
Seminars in Roentgenology.2021; 56(2): 186. CrossRef
Advances in radiological staging of colorectal cancer
R.J. Goiffon, A. O'Shea, M.G. Harisinghani
Clinical Radiology.2021; 76(12): 879. CrossRef
A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer
Klara Hammarström, Israa Imam, Artur Mezheyeuski, Joakim Ekström, Tobias Sjöblom, Bengt Glimelius
Cancers.2020; 13(1): 16. CrossRef

8,644 View
174 Download
7 Web of Science
7 Crossref

Redefining the Positive Circumferential Resection Margin by Incorporating Preoperative Chemoradiotherapy Treatment Response in Locally Advanced Rectal Cancer: A Multicenter Validation Study: Joo Ho Lee, Eui Kyu Chie, Seung-Yong Jeong, Tae-You Kim, Dae Yong Kim, Tae Hyun Kim, Sun Young Kim, Ji Yeon Baek, Hee Jin Chang, Min Ju Kim, Sung Chan Park, Jae Hwan Oh, Sung Hwan Kim, Jong Hoon Lee, Doo Ho Choi, Hee Chul Park, Sung-Bum Kang, Jae-Sung Kim; Cancer Res Treat. 2018;50(2):506-517. Published online May 24, 2017; DOI: https://doi.org/10.4143/crt.2016.607

Abstract PDF PubReader ePub

Purpose
This study was conducted to validate the prognostic influence of treatment response among patients with positive circumferential resection margin for locally advanced rectal cancer.
Materials and Methods
Clinical data of 197 patientswith positive circumferentialresection margin defined as ≤ 2 mm after preoperative chemoradiotherapy followed by total mesorectal excision between 2004 and 2009were collected forthis multicenter validation study. All patients underwent median 50.4Gy radiationwith concurrentfluoropyrimidine based chemotherapy. Treatmentresponse was dichotomized to good response, including treatmentresponse of grade 2 or 3, and poor response, including grade 0 or 1.
Results
After 52 months median follow-up, 5-year overall survival (OS) for good responders and poor responders was 79.1% and 48.4%, respectively (p < 0.001). In multivariate analysis, circumferential resection margin involvement and treatment response were a prognosticator for OS and locoregional recurrence-free survival. In subgroup analysis, good responders with close margin showed significantly better survival outcomes for survival. Good responders with involved margin and poor responders with close margin shared similar results, whereas poorresponderswith involved margin hadworst survival (5-year OS, 81.2%, 57.0%, 50.0%, and 32.4%, respectively; p < 0.001).
Conclusion
Among patients with positive circumferential resection margin after preoperative chemoradiotherapy, survival of the good responders was significantly better than poor responders. Subgroup analysis revealed that definition of positive circumferential resection margin may be individualized as involvement for good responders, whereas ≤ 2 mm for poor responders.

Citations

Citations to this article as recorded by

Tailored Strategy for Locally Advanced Rectal Carcinoma (GRECCAR 4): Long-term Results From a Multicenter, Randomized, Open-Label, Phase II Trial
Philippe Rouanet, Eric Rullier, Bernard Lelong, Philippe Maingon, Jean-Jacques Tuech, Denis Pezet, Florence Castan, Stephanie Nougaret
Diseases of the Colon & Rectum.2022; 65(8): 986. CrossRef
Colorectal Cancer Surgery Quality in Manitoba: A Population-Based Descriptive Analysis
Iresha Ratnayake, Jason Park, Natalie Biswanger, Allison Feely, Grace Musto, Kathleen Decker
Current Oncology.2021; 28(3): 2239. CrossRef

11,361 View
266 Download
4 Web of Science
2 Crossref

Correspondence

Colorectal Cancer Incidence in Korea Is Not the Highest in the World: Aesun Shin, Kyu-Won Jung, Hyeongtaek Woo, Seung-Yong Jeong; Cancer Res Treat. 2016;48(2):864-867. Published online January 28, 2016; DOI: https://doi.org/10.4143/crt.2015.484

PDF PubReader ePub

Citations

Citations to this article as recorded by

Spectrum of Colorectal Adenocarcinomas: A 4 year experience in a tertiary care centre from Western Maharashtra
Rachana Lakhe, Amrutraj Patil, Rajeev Doshi, Preeti Doshi, Milind Kesarkhane, Ravindra Nimbargi
IP Journal of Diagnostic Pathology and Oncology.2023; 8(2): 79. CrossRef
Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery
Leszek Kozlowski, Katarzyna Bielawska, Alena Zhymaila, Jolanta Malyszko
Diagnostics.2022; 12(9): 2137. CrossRef
Long-Term Risks of Parkinson’s Disease, Surgery, and Colorectal Cancer in Patients With Slow-Transit Constipation
Eun Mi Song, Hyo Jeong Lee, Kee Wook Jung, Mi Jung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Jaewon Choe, Suk-Kyun Yang, Satish S.C. Rao, Seung-Jae Myung
Clinical Gastroenterology and Hepatology.2021; 19(12): 2577. CrossRef
Colorectal cancer in the United States and a review of its heterogeneity among Asian American subgroups
Mofan Gu, Susan Thapa
Asia-Pacific Journal of Clinical Oncology.2020; 16(4): 193. CrossRef
Real-World National Colonoscopy Volume in Korea: A Nationwide Population-Based Study over 12 Years
Jae Myung Cha, Min Seob Kwak, Hyun-Soo Kim, Su Young Kim, Sohee Park, Geun U Park, Jung Kuk Lee, Soo Jin Kim, Hun Hee Lee, Joo Sung Kim, Won Ho Kim
Gut and Liver.2020; 14(3): 338. CrossRef
The Combined Impact of Chronic Kidney Disease and Diabetes on the Risk of Colorectal Cancer Depends on Sex: A Nationwide Population-Based Study
Hyung Jung Oh, Hye Ah Lee, Chang Mo Moon, Dong-Ryeol Ryu
Yonsei Medical Journal.2020; 61(6): 506. CrossRef
A Report of Bone Marrow Metastasis of Colon Cancer as a Primary Diagnosis, Supported by Cytokeratin Immunohistochemical Staining
Bohyun Kim, Kyu Taek Lee
Laboratory Medicine Online.2019; 9(2): 103. CrossRef
Defensin alpha 6 (DEFA6) is a prognostic marker in colorectal cancer
Dongjun Jeong, Hyeongjoo Kim, Doyeon Kim, Seona Ban, Seunghyun Oh, Sanghee Ji, DongHyun Kang, Hyunyong Lee, Tae Sung Ahn, Han Jo Kim, Sang Byung Bae, Moon Soo Lee, Chang-Jin Kim, Hyog Young Kwon, Moo-Jun Baek
Cancer Biomarkers.2019; 24(4): 485. CrossRef
Colorectal cancer epidemiology in Korea
Aesun Shin, Doeun Jang, Sunho Choe, Young-Joo Won, Kyu-Won Jung, Ji Won Park, Seung-Yong Jeong
Journal of the Korean Medical Association.2019; 62(8): 407. CrossRef
Effect of Dietary Red Meat on Colorectal Cancer Risk—A Review
Sun Jin Hur, Yohan Yoon, Cheorun Jo, Jong Youn Jeong, Keun Taik Lee
Comprehensive Reviews in Food Science and Food Safety.2019; 18(6): 1812. CrossRef
Risk Factors for Colorectal Cancer in Korea: A Population-Based Retrospective Cohort Study
Soomin Nam, Yoon Jung Choi, Dong Wook Kim, Eun-Cheol Park, Jung-Gu Kang
Annals of Coloproctology.2019; 35(6): 347. CrossRef
Interaction between physical activity,PITX1rs647161 genetic polymorphism and colorectal cancer risk in a Korean population: a case-control study
Madhawa Neranjan Gunathilake, Jeonghee Lee, Young Ae Cho, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
Oncotarget.2018; 9(7): 7590. CrossRef
The Study for Incidence Trends of Colorectal Cancer in Jeju-do
Weon-Young Chang
Journal of the Korea Academia-Industrial cooperation Society.2016; 17(5): 566. CrossRef
Transmissibility of the Campaign for Colorectal Cancer Awareness in Korea Among Twitter Users
Keun Chul Lee, Heung-Kwon Oh, Gibeom Park, SoHyun Park, Bongwon Suh, Woo Kyung Bae, Jin Won Kim, Hyuk Yoon, Myung Jo Kim, Sung-Il Kang, Il Tae Son, Duck-Woo Kim, Sung-Bum Kang
Annals of Coloproctology.2016; 32(5): 184. CrossRef

10,960 View
109 Download
10 Web of Science
14 Crossref

Original Articles

Validation of Prediction Models for Mismatch Repair Gene Mutations in Koreans: Soo Young Lee, Duck-Woo Kim, Young-Kyoung Shin, Myong Hoon Ihn, Sung Min Lee, Heung-Kwon Oh, Ja-Lok Ku, Seung-Yong Jeong, Jae Bong Lee, Soyeon Ahn, Sungho Won, Sung-Bum Kang; Cancer Res Treat. 2016;48(2):668-675. Published online June 5, 2015; DOI: https://doi.org/10.4143/crt.2014.288

Abstract PDF PubReader ePub

Purpose
Lynch syndrome, the commonest hereditary colorectal cancer syndrome, is caused by germline mutations in mismatch repair (MMR) genes. Three recently developed prediction models for MMR gene mutations based on family history and clinical features (MMRPredict, PREMM1,2,6, and MMRPro) have been validated only in Western countries. In this study, we propose validating these prediction models in the Korean population.
Materials and Methods
We collected MMR gene analysis data from 188 individuals in the Korean Hereditary Tumor Registry. The probability of gene mutation was calculated using three prediction models, and the overall diagnostic value of each model compared using receiver operator characteristic (ROC) curves and area under the ROC curve (AUC). Quantitative test characteristics were calculated at sensitivities of 90%, 95%, and 98%.
Results
Of the individuals analyzed, 101 satisfied Amsterdam criteria II, and 87 were suspected hereditary nonpolyposis colorectal cancer. MMR mutations were identified in 62 of the 188 subjects (33.0%). All three prediction models showed a poor predictive value of AUC (MMRPredict, 0.683; PREMM1,2,6, 0.709; MMRPro, 0.590). Within the range of acceptable sensitivity (> 90%), PREMM1,2,6 demonstrated higher specificity than the other models.
Conclusion
In the Korean population, overall predictive values of the three models (MMRPredict, PREMM1,2,6, MMRPro) for MMR gene mutations are poor, compared with their performance in Western populations. A new prediction model is therefore required for the Korean population to detect MMR mutation carriers, reflecting ethnic differences in genotype-phenotype associations.

Citations

Citations to this article as recorded by

Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan
Fei‐Hung Hung, Hung‐Pin Peng, Chen‐Fang Hung, Ling‐Ling Hsieh, An‐Suei Yang, Yong Alison Wang
International Journal of Cancer.2024; 155(12): 2201. CrossRef
Absence of constitutional MLH1 promoter methylation in Pakistani colorectal cancer patients
Ayesha Azeem, Humaira Naeemi, Noor Muhammad, Asif Loya, Muhammed Aasim Yusuf, Muhammad Usman Rashid
Gene Reports.2024; 36: 101995. CrossRef
Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients
Muhammad Usman Rashid, Humaira Naeemi, Noor Muhammad, Asif Loya, Jan Lubiński, Anna Jakubowska, Muhammed Aasim Yusuf
Hereditary Cancer in Clinical Practice.2019;[Epub] CrossRef
Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers
A. Goverde, M. C. W. Spaander, D. Nieboer, A. M. W. van den Ouweland, W. N. M. Dinjens, H. J. Dubbink, C. J. Tops, S. W. ten Broeke, M. J. Bruno, R. M. W. Hofstra, E. W. Steyerberg, A. Wagner
Familial Cancer.2018; 17(3): 361. CrossRef
Advances in Hereditary Colorectal and Pancreatic Cancers
Meghan L. Underhill, Katharine A. Germansky, Matthew B. Yurgelun
Clinical Therapeutics.2016;[Epub] CrossRef

14,353 View
88 Download
4 Web of Science
5 Crossref

Clinicopathological Features and Type of Surgery for Lynch Syndrome: Changes during the Past Two Decades: Il Tae Son, Duck-Woo Kim, Seung-Yong Jeong, Young-Kyoung Shin, Myong Hoon Ihn, Heung-Kwon Oh, Sung-Bum Kang, Kyu Joo Park, Jae Hwan Oh, Ja-Lok Ku, Jae-Gahb Park; Cancer Res Treat. 2016;48(2):605-611. Published online May 26, 2015; DOI: https://doi.org/10.4143/crt.2015.092

Abstract PDF PubReader ePub

Purpose
The Korean Hereditary Tumor Registry, the first and one of the largest registries of hereditary tumors in Korea, has registered about 500 families with hereditary cancer syndromes. This study evaluates the temporal changes in clinicopathologic features and surgical patterns of Lynch syndrome (LS) patients.
Materials and Methods
Data on 182 unrelated LS patients were collected retrospectively. The patients were divided into the period 1 group (registered in 1990-2004) and 2 (registered in 2005-2014). The clinical characteristics of the two groups were compared to identify changes over time.
Results
The period 1 group included 76 patients; the period 2 group, 106 patients. The mean ages at diagnosis were 45.1 years (range, 13 to 85 years) for group 1 and 49.7 years (range, 20 to 84 years) for group 2 (p=0.015). The TNM stage at diagnosis did not differ significantly— period 1 group: stage 0-I (n=18, 23.7%), II (n=37, 48.7%), III (n=19, 25.0%), and IV (n=2, 2.6%); period 2 group: stage 0-I (n=30, 28.3%), II (n=35, 33.0%), III (n=37, 34.9%), and IV (n=4, 3.8%). Extended resection was more frequently performed (55/76, 72.4%) in the period 1 group than period 2 (49/106, 46.2%) (p=0.001).
Conclusion
Colorectal cancer in patients with LS registered at the Korean Hereditary Tumor Registry is still diagnosed at an advanced stage, more than two decades after registry’s establishment. Segmental resection was more frequently performed in the past decade. A prompt nationwide effort to raise public awareness of hereditary colorectal cancer and to support hereditary cancer registries is required in Korea.

Citations

Citations to this article as recorded by

Universal Screening for Lynch Syndrome Compared with Pedigree-Based Screening: 10-Year Experience in a Tertiary Hospital
Min Hyun Kim, Duck-Woo Kim, Hye Seung Lee, Su Kyung Bang, Soo Hyun Seo, Kyung Un Park, Heung-Kwon Oh, Sung-Bum Kang
Cancer Research and Treatment.2023; 55(1): 179. CrossRef
Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all?
Chun-Kai Liao, Yueh-Chen Lin, Yu-Jen Hsu, Yih-Jong Chern, Jeng-Fu You, Jy-Ming Chiang
Hereditary Cancer in Clinical Practice.2021;[Epub] CrossRef
Comparison of oncologic outcomes between patients with Lynch syndrome and sporadic microsatellite instability-high colorectal cancer
Il Tae Son, Duck-Woo Kim, Min Hyun Kim, Young-Kyoung Shin, Ja-Lok Ku, Heung-Kwon Oh, Sung-Bum Kang, Seung-Yong Jeong, Kyu Joo Park
Annals of Surgical Treatment and Research.2021; 101(1): 13. CrossRef
Germline Variants in MLH1, MSH2, and MSH6 in Korean Patients with Lynch Syndrome
Kyoung-Jin Park, Dong Kyung Chang, Hee Cheol Kim, Jong-Won Kim
Laboratory Medicine Online.2018; 8(4): 156. CrossRef
Efficacy, functional outcome and post‑operative complications of total abdominal colectomy with ileorectal anastomosis vs. segmental colectomy in hereditary non‑polyposis colorectal cancer
Jie Sun, Mingjie Dong, Xiaoping Xiao
Experimental and Therapeutic Medicine.2018;[Epub] CrossRef

12,249 View
106 Download
4 Web of Science
5 Crossref

Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia: Dae Kyung Sohn, Seung-Yong Jeong, Hyo Seong Choi, Seok-Byung Lim, Jin Myeong Huh, Dae-Hyun Kim, Dae Yong Kim, Young Hoon Kim, Hee Jin Chang, Kyung Hae Jung, Joong-Bae Ahn, Hyun Kyung Kim, Jae-Gahb Park; Cancer Res Treat. 2005;37(1):20-23. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.20

Abstract PDF PubReader ePub

Purpose

This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia.

Materials and Methods

A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia®, Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer® (Eiken Chemical Co. Tokyo, Japan).

Results

Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively.

Conclusion

The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.

Citations

Citations to this article as recorded by

Interval Advanced Adenomas and Neoplasia in Patients with Negative Colonoscopy Following Positive Stool-Based Colorectal Cancer Screening Test
Kyle S. Liu, Rollin George, Caleb Shin, Jia Q. Xiong, Taher Jamali, Yan Liu, Priya Roy, Sonia Singh, Samuel Ma, Hashem B. El-Serag, Mimi C. Tan
Digestive Diseases and Sciences.2025; 70(1): 350. CrossRef
Findings in the distal and proximal colon in colonoscopy screening after positive FIT and related pre-procedure factors
M.� Henar Núñez Rodríguez, Pilar Díez Redondo, Fausto Riu Pons, Marta Cimavilla, Andrea Loza, Manuel Perez-Miranda
Revista Española de Enfermedades Digestivas.2022;[Epub] CrossRef
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
Esmée J Grobbee, Pieter HA Wisse, Eline H Schreuders, Aafke van Roon, Leonie van Dam, Ann G Zauber, Iris Lansdorp-Vogelaar, Wichor Bramer, Sarah Berhane, Jonathan J Deeks, Ewout W Steyerberg, Monique E van Leerdam, Manon CW Spaander, Ernst J Kuipers
Cochrane Database of Systematic Reviews.2022;[Epub] CrossRef
Potential Modifiers and Different Cut-offs in Diagnostic Accuracy of Fecal Immunochemical Test in Detecting Advanced Colon Neoplasia: A Diagnostic Test Accuracy Meta-analysis
Mohammad Yaghoobi, Parsa Mehraban Far, Lawrence Mbuagbaw, Yuhong Yuan, David Armstrong, Lehana Thabane, Paul Moayyedi
Middle East Journal of Digestive Diseases.2022; 14(4): 382. CrossRef
Guidelines for accreditation of endoscopy units: quality measures from the Korean Society of Coloproctology
Rumi Shin, Seongdae Lee, Kyung-Su Han, Dae Kyung Sohn, Sang Hui Moon, Dong Hyun Choi, Bong-Hyeon Kye, Hae-Jung Son, Sun Il Lee, Sumin Si, Won-Kyung Kang
Annals of Surgical Treatment and Research.2021; 100(3): 154. CrossRef
Screening for Colorectal Cancer
Jennifer S. Lin, Leslie A. Perdue, Nora B. Henrikson, Sarah I. Bean, Paula R. Blasi
JAMA.2021; 325(19): 1978. CrossRef
Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy
Nao Kobayashi, Takahiro Oike, Nobuteru Kubo, Yuhei Miyasaka, Tatsuji Mizukami, Hiro Sato, Akiko Adachi, Hiroyuki Katoh, Hidemasa Kawamura, Tatsuya Ohno
Cancers.2021; 13(17): 4481. CrossRef
Evaluation of the Cut-Off Value of Fecal Immunochemical Test for Colorectal Cancer Screening during Health Checkups
Hye-Ran Park, Eun-Hee Nah, Jong-Seon Lee, Seon Cho
Journal of Laboratory Medicine and Quality Assurance.2021; 43(4): 190. CrossRef
Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis
Tobias Niedermaier, Yesilda Balavarca, Hermann Brenner
American Journal of Gastroenterology.2020; 115(1): 56. CrossRef
Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location
Tobias Niedermaier, Kaja Tikk, Anton Gies, Stefanie Bieck, Hermann Brenner
Clinical Gastroenterology and Hepatology.2020; 18(13): 2920. CrossRef
Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps
Thomas F. Imperiale, Rachel N. Gruber, Timothy E. Stump, Thomas W. Emmett, Patrick O. Monahan
Annals of Internal Medicine.2019; 170(5): 319. CrossRef
Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis
Kevin Selby, Emma H. Levine, Cecilia Doan, Anton Gies, Hermann Brenner, Charles Quesenberry, Jeffrey K. Lee, Douglas A. Corley
Gastroenterology.2019; 157(6): 1494. CrossRef
Quantitative fecal immunochemical tests for colorectal cancer screening
Anton Gies, Megha Bhardwaj, Christian Stock, Petra Schrotz‐King, Hermann Brenner
International Journal of Cancer.2018; 143(2): 234. CrossRef
Prevalence of functional gastrointestinal disorders in adults with systemic lupus erythematosus
M García-Carrasco, C Mendoza-Pinto, M A Autrán-Limón, E Herrera Robles, S Méndez Martínez, I Etchegaray Morales, Á Montiel Jarquín, J L Gálvez Romero, P Soto-Santillán, J Galindo-Herrera, A López-Colombo
Lupus.2018; 27(5): 788. CrossRef
Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea
Dae Ho Kim, Jae Myung Cha, Min Seob Kwak, Jin Young Yoon, Young-Hak Cho, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Gut and Liver.2018; 12(2): 183. CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastroenterology.2017; 152(5): 1217. CrossRef
Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastrointestinal Endoscopy.2017; 85(1): 2. CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J Robertson, Jeffrey K Lee, Richard C Boland, Jason A Dominitz, Francis M Giardiello, David A Johnson, Tonya Kaltenbach, David Lieberman, Theodore R Levin, Douglas K Rex
American Journal of Gastroenterology.2017; 112(1): 37. CrossRef
Risk Factors for False Fecal Immunochemical Test Results in Colorectal Cancer Screening
Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
Journal of Clinical Gastroenterology.2017; 51(2): 151. CrossRef
Which Fecal Immunochemical Test Should I Choose?
Jeanette M. Daly, Yinghui Xu, Barcey T. Levy
Journal of Primary Care & Community Health.2017; 8(4): 264. CrossRef
Cancer-Type Oatp1B3 mRNA Has the Potential to Become a Detection and Prognostic Biomarker for Human Colorectal Cancer
Yuchen Sun, Manami Harada, Osamu Shimozato, Hiroaki Souda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Takehiko Kamijo, Hidetaka Akita, Naohiko Anzai, Kan Chiba, Tomomi Furihata
Biomarkers in Medicine.2017; 11(8): 629. CrossRef
Screening of colorectal cancer: present and future
Marcello Maida, Fabio Salvatore Macaluso, Gianluca Ianiro, Francesca Mangiola, Emanuele Sinagra, Georgina Hold, Carlo Maida, Giovanni Cammarota, Antonio Gasbarrini, Giuseppe Scarpulla
Expert Review of Anticancer Therapy.2017; 17(12): 1131. CrossRef
Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance
Min Seob Kwak, Jae Myung Cha, Jin Young Yoon, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Journal of Clinical Gastroenterology.2017; 51(9): 825. CrossRef
Accuracy of Fecal Immunochemical Tests for Colorectal Cancer
Jeffrey K. Lee, Elizabeth G. Liles, Stephen Bent, Theodore R. Levin, Douglas A. Corley
Annals of Internal Medicine.2014; 160(3): 171. CrossRef
Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim
Digestive Diseases and Sciences.2013; 58(11): 3256. CrossRef
Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim, Sang-Hyun Hwang
Digestive Diseases and Sciences.2012; 57(8): 2178. CrossRef
A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program
Mi Jin Park, Kui Son Choi, You Kyoung Lee, Jae Kwan Jun, Hoo-Yeon Lee
Scandinavian Journal of Gastroenterology.2012; 47(4): 461. CrossRef
Clinical Features of Colorectal Cancer Detected by the National Cancer Screening Program
Dae-Do Park, Rumi Shin, Ji-Sun Kim, Heung-Kwon Oh, Seung-Yong Jeong, Kyu Joo Park, Jae-Gahb Park
Journal of the Korean Society of Coloproctology.2010; 26(6): 420. CrossRef
The Significance of Fecal Immunochemical Test to Screen for Colorectal Cancer in National Cancer Screening Program
Jun Uk Lim, Na Young Bae, Won Koung Song, Jae Myung Cha, Joung Il Lee
Intestinal Research.2010; 8(2): 126. CrossRef
False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening
Leo G.M. van Rossum, Anne F. van Rijn, Martijn G.H. van Oijen, Paul Fockens, Robert J.F. Laheij, Andre L.M. Verbeek, Jan B.M.J. Jansen, Evelien Dekker
International Journal of Cancer.2009; 125(4): 746. CrossRef
Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme
L G M van Rossum, A F van Rijn, R J F Laheij, M G H van Oijen, P Fockens, J B M J Jansen, A L M Verbeek, E Dekker
British Journal of Cancer.2009; 101(8): 1274. CrossRef
Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population
Leo G. van Rossum, Anne F. van Rijn, Robert J. Laheij, Martijn G. van Oijen, Paul Fockens, Han H. van Krieken, Andre L. Verbeek, Jan B. Jansen, Evelien Dekker
Gastroenterology.2008; 135(1): 82. CrossRef

11,256 View
89 Download
32 Crossref

First
Prev
Page of 1
Next
Last

Search